Context: To date, established risk factors for prostate cancer (PCa) are limited to age, race, family history, and certain genetic polymorphisms. Despite great research efforts, available evidence on potentially modifiable risk factors is conflicting. Moreover, most studies on PCa risk factors did not consider the impact of prostate-specific antigen (PSA) testing on PCa diagnosis. Objective: To provide a detailed overview of the latest evidence on the role of metabolic diseases, drugs, and dietary factors for risk of PCa incidence, recurrence, and survival in men exposed to PSA testing. Evidence acquisition: A systematic review of the English-language literature was performed using the MEDLINE, Cochrane Central Register of Controlled Trials, and Web of Science databases according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses recommendations. Randomized, case-control, or cohort studies published during the periods 2008-2017 (on drugs and metabolic diseases) and y These authors have equally contributed to senior authorship. (on dietary factors), with extensive follow-up (!8-10 yr for studies on PCa risk; !2-5 yr for studies on PCa recurrence, progression, and survival, depending on the review subtopic) and adjusting of the analyses, beyond established risk factors, for either rate of PSA testing (for risk analyses) or PCa stage and primary treatment (for survival analyses), were eligible for inclusion. Evidence synthesis: Overall, 39 reports from 22 observational studies were included. Studies were heterogeneous regarding definitions of exposure or outcomes, length of follow-up, risk of bias, and confounding. For some risk factors, evidence was insufficient to assess potential effects, while for others there was no evidence of an effect. For selected risk factors, namely metformin, aspirin and statin use, diabetes, obesity, and specific dietary intakes, there was low-quality evidence of modest effects on PCa risk. Conclusions: Current evidence from long-term observational studies evaluating the effect of drugs, metabolic diseases, and dietary factors for PCa risk considering the impact of PSA testing is still not conclusive. Future research is needed to confirm the associations suggested by our review, exploring their potential biological explanations and selecting those risk factors most likely to trigger effective public health interventions. Patient summary: We reviewed the available studies published in the recent literature on the potential role of drugs, metabolic diseases, and food and dietary factors for the risk of prostate cancer, considering the impact of prostate-specific antigen testing on prostate cancer diagnosis. We found that for some factors data are currently insufficient to make definitive conclusions, while for others available studies seem to indicate an effect on the risk of prostate cancer.
1.

Introduction
Prostate cancer (PCa) is a major public health problem worldwide [1, 2] . To date, established risk factors are limited to age, race, family history, and certain genetic polymorphisms [3] [4] [5] [6] [7] . Despite great research efforts, available evidence on potentially modifiable risk factors remains conflicting [6] . This is partly explained by the limitations of available studies in terms of heterogeneous design, short follow-up, risk of bias (RoB), and confounding. Consequently, no definitive recommendations can be provided for specific preventive or dietary measures to reduce PCa risk [8, 9] .
Of note, patterns and temporal trends in PCa incidence have largely been influenced by prostate-specific antigen (PSA) testing and diagnostic ascertainment [4, 5] . Genetic and environmental factors may play a role in the persistent geographical incidence differences despite different levels of PSA testing [5] ; however, such risk factors still remain elusive and none of them could have caused an extremely rapid rise in PCa incidence, as observed in most countries using PSA testing [4, 5] .
In this scenario, despite controversies over whether it is beneficial in reducing disease-specific mortality [6, 7, 9] , PSA testing has been and is currently widely used in many populations [2, 4, 5] , making it difficult to disentangle the potential impact of specific PCa risk factors without considering the bias given by the differential rate of PSA testing.
In this scenario, testing the role of potentially modifiable factors for PCa risk in men exposed to PSA testing is a distinct unmet need.
Herein, we provide a detailed overview of the latest evidence from long-term studies evaluating the differential impact of metabolic diseases, drugs, and dietary factors on PCa risk considering the effect of PSA testing.
Evidence acquisition
The review process was performed in accordance with the European Association of Urology (EAU) methodology on the key steps in conducting systematic reviews [10] and the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement recommendations [11] .
Search strategy
Sensitive computerized bibliographic searches were performed using MEDLINE (via PubMed), Cochrane Central Register of Controlled Trials, and Web of Science databases in December 2017. The detailed review strategy, including full search strategy and keywords, is presented in the Supplementary material. The search strategy was designed using both free text and mesh terms applying a time period (2008-2017 and 2003-2017 for the subchapters "drugs/ metabolic diseases" and "food and dietary factors," respectively) and "English" language filters. Hand search of bibliographies of included studies and previous systematic reviews was also performed to include additional potentially relevant studies.
Inclusion criteria
As recommended by PRISMA and EAU methodology, a specific population (P), intervention (I), comparator (C), outcome (O), and study design (S; PICOS) framework defined study eligibility (Supplementary material) [10, 11] . In brief, studies were considered eligible for this systematic review if they fulfilled the following criteria: (1) population exposed to PSA testing and composed by adult (>18 yr) men without proven PCa (for PCa risk analysis [O] ), or adult men with previous confirmed PCa (P) (for PCa recurrence/survival analyses [O]) "exposed" or "unexposed" (C) to the putative risk factor for PCa (I); (2) randomized controlled or prospective cohort study design with longterm follow-up (!8/10 yr, for studies on PCa risk for the subtopics "dietary factors" and drugs/metabolic diseases, respectively, and !2/5 yr for studies on PCa recurrence/ survival for the subtopics "dietary factors" and drugs/metabolic diseases, respectively) or case-control study design (S); and (3) adjustment of statistical analyses at least for age, race, family history of PCa, rate of PSA testing, PSA (for risk analysis) or PCa stage, and primary treatment (for recurrence/survival analyses; S). The rational for including only studies with analyses adjusted for rate of PSA testing is grounded in the current evidence on the impact of PSA testing on PCa diagnosis [1, 2, 4, 5, 7] .
Observational studies with insufficient reporting of the PICOS criteria according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement recommendations [12] were excluded.
Systematic review process
Mendeley reference software was used to identify and remove duplicates among records identified. After further exclusion of records not related to this review, two independent authors (R.C. and A.M.) screened titles and abstracts of 2543 records related to metabolic diseases and drugs, while two other independent authors (J.D.S.H. and O.R.F.) screened titles and abstracts of 592 records related to food and dietary factors. Disagreement was solved by a third party (S.B.M.) supervising the systematic review process. The same authors carried out the study selection. Separate screening forms were created for each selection phase and adapted to each review subchapter, as appropriate. The flowchart depicting the overall review process according to PRISMA is shown in Fig. 1 .
Data extraction
Data were extracted independently by two authors (R.C. and O.R.F.) in an a priori developed, standardized data extraction form adapted for each subtopic of the review. This included information on all elements of the PICOS framework, as well as confounders adjusted for in statistical analysis. RoB assessment in observational studies was performed independently by two authors (R.C. and A.M.) according to both Quality in Prognosis Studies tool [13] and Newcastle-Ottawa Scale [14] ( Supplementary Tables 1 and 2 ). Disagreement was solved by a third party (S.B.M.). Overall quality of evidence was assessed according to Grading of Recommendations Assessment, Development, and Evaluation (GRADE) recommendations [15] . A narrative form was used for qualitative data synthesis.
Evidence synthesis
Overall, 39 reports from 22 observational studies were included in final qualitative analysis ( Fig. 1) . Key study findings are shown in Tables 1-3 , while additional information regarding design and participant characteristics in studies on drugs and metabolic diseases are given in Supplementary Tables 3 and 4 .
Overall, most studies included predominantly Caucasian populations with an average age at baseline of 55-65 yr and an average age at diagnosis of 65-70 yr.
Quantification of intensity of PSA testing was variable across the included studies ( Supplementary Table 3 ), ranging from "the number of PSA tests in the last 2 [16] [17] [18] , 3 [19] , or 5 yr" [20] [21] [22] to "a positive history of PSA screening" [23] .
In three studies ( Table 3 ).
According to GRADE [15] , overall quality of evidence of studies on all subtopics was low. RoB was generally higher for studies on the topic "food and dietary factors" (compared with the other subtopics) and for studies with a casecontrol study design (Supplementary Tables 1 and 2).
Drugs and PCa
Overall, 16 reports from eight studies were included, of which 11 were on PCa incidence and five on PCa survival (Table 1 ).
3.1.1. Drugs and PCa incidence 3.1.1.1. Antidiabetic drugs. In a prospective cohort study (PCS) from the FinRSP cohort [24] , use of metformin (compared with the use of other oral antidiabetic drugs) was associated with a lower risk of PCa, with a significant inverse trend with increasing amount, duration, and intensity of use. However, the decrease in risk was significant only in the screening arm, raising concerns on the risk of potential detection bias due to the lower baseline PSA value in metformin users before randomization. Use of insulin and other antidiabetic drugs was not associated with overall PCa risk. On the contrary, the risk of metastatic PCa was higher in sulfonylurea users (hazard ratio [HR] 2.04, 95% confidence interval [CI] 1.11-3.77), suggesting hyperinsulinemia as a risk factor for PCa progression. A population-based case-control study (PBCC) from Denmark [20] found that metformin use was associated with a decreased risk of PCa (adjusted odds ratio [aOR] 0.84, 95% CI 0.74-0.96) and, in particular, localized disease (aOR 0.70, 95% CI 0.57-0.87), while no association with locally advanced or distant metastatic disease was found. Both increasing duration and intensity of metformin use were associated with a decreasing incidence of PCa. However, the decreased risk of PCa was found only in diabetics with a !6yr history (aOR 0.81, 95% CI 0.69-0.96). No significant associations were found between the use of other antidiabetic drugs (including insulin) and PCa risk.
3.1.1.2. Statins. In a PBCC study from the USA [25] , statin use was not associated with the risk of overall or grade-/stagespecific PCa.
3.1.1.3. Aspirin. In a PCS from the Health Professionals Follow-up Study (HPFS) cohort [26] , consumption of at least two adult-strength aspirin tablets a week was associated with a 10% lower risk of overall PCa, with no material difference in the risk for higher levels of frequency, duration, or frequency of use. Only men older than 65 yr experienced reduced risks. Most measurements of aspirin use were also associated with modest decreases in the risk of high-grade PCa, with a significant dose relationship for tablets per week. PSA testing did not change the overall set of results.
In a subsequent study from the same cohort with 32 yr of follow-up, regular use of aspirin was not associated with the risk of advanced (!T3b, N1, or M1 at diagnosis) PCa, even considering the potential effect of PSA testing [16] .
In a PCS from the PLCO Cancer Screening Trial cohort [27] , daily use of aspirin was significantly associated with a lower risk of PCa (HR [95% CI] 0.91 [0.84-0.99]). The risk was similar considering men taking one or more pill of aspirin per day (vs never use); however, this inverse association appeared to be more pronounced among men aged >65 yr and in those who reported a history of cardiovascular- 
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Iden fica on Screening Eligibility Included Fig. 1 -Flow-diagram showing the step-by-step review process according to the PRISMA statement criteria. The detailed strategy for records identification and selection is provided in the Supplementary material. PCa = prostate cancer; PICO = population, intervention, comparator, and outcome; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analyses; WOS = Web of Science. In sensitivity analysis limited to patients with a PSA test, metformin use was associated with a decreased risk of PCa compared with nonuse (aOR 0.66; 95% CI 0.51-0.86). In the stage-stratified analysis, metformin use was associated with a reduced risk of localized cancer (aOR 0.70; 95% CI 0.57-0.87), but not regional or distant metastatic PCa. Increasing duration or intensity of metformin use was associated with decreasing incidence of PCa (durations of 3-5 yr: aOR 0.76; 95% CI 0.58-1.01; >5 yr: aOR 0.75; 95% CI 0.57-0.98). 2. Metformin use was not associated with decreased risk of PCa only in diabetics with a >6-yr history (aOR 0.81; 95% CI 0.69-0.96). 3. A reduced risk of PCa was associated with insulin use but not with the use of other antidiabetic medications. In the sensitivity analysis limited to patients with a PSA test, no significant reduction in PCa risk among users of insulin and other diabetic medications use were found. Statins When compared with NSAID nonusers, the overall PCa risk was elevated among current NSAID prescription users (HR 1.45, 95% CI 1.33-1.59 and HR 1.32, 95% CI 1.10-1.59 in the screening and the control arm, respectively). Previous use or over-the-counter use was not associated with PCa risk. A similar risk association was also observed for acetaminophen, but not for aspirin. Both current and previous coxib uses were associated with an elevated PCa risk. The increased PCa risk associated with overall NSAID, coxib, and acetaminophen use was not modified by tumor grade. The association between NSAID use and PCa risk was not modified by cumulative COX-2 inhibition. Stratification by the use of other drug groups or NSAIDs before randomization, Charlson comorbidity index, or propensity for NSAID use did not modify the risk association with PCa. 2. Current, but not previous, use of prescription NSAIDs, coxibs, and acetaminophen was associated with an elevated risk of metastatic PCa in both trial arms. Aspirin use was not significantly associated with metastatic PCa risk, with the exception of elevated risk among prescription users in the control arm. Intensity of NSAID and coxib use was directly correlated with the risk of metastatic PCa after adjustment for the use of other drugs. Jacobs et al (2011) [30] Regular aspirin and ibuprofen use (at study entry) Incidence of total, aggressive (GS !7 or stage III-IV) PCa a AC: study center, aspirin (for ibuprofen) and ibuprofen (for aspirin) use, physical activity, dietary fat consumption, other dietary factors 1. Daily use of aspirin only was significantly associated with a lower risk of PCa with an HR (95% CI) of 0.91 (0.84-0.99). There was no evidence of an association between ibuprofen use and PCa risk. 2. Risks associated with daily aspirin use were similar, but slightly lower for aggressive than for nonaggressive cancers. History of various medical conditions (including diabetes, hypertension, stroke, heart attack, arthritis) did not appreciably modify the association between the use of either drugs and PCa risk. 3. The risk for PCa associated with taking !1 pill of aspirin per day (vs never use) was 0.92 (95% CI 0.85-0.99). A significant negative trend with the frequency of aspirin use (p for trend 0.04) was observed. 4. In stratified analysis, the inverse associations appeared more pronounced among men taking !1 pill of aspirin daily who were older than 65 yr (HR [95% CI] of 0.87 [0.78-0.97]) and who reported having a history of cardiovascular-related diseases (HR [95% CI] 0.89 [0.80-0.99]) or arthritis (HR [95% CI] 0.88 [0.78-1.00]) despite the lack of significant interaction. Postdiagnostic regular aspirin use (taking >3 tablets/wk for at least 1 yr) Incidence of lethal (M+ or PCa-specific death) PCa and PCa-specific survival AC for risk analysis: BMI, height, smoking, hypertension, type 2 diabetes (yes vs no) No formal adjustment for PSA screening AC for survival analysis: Charlson comorbidity index, BMI, smoking, hypertension, type 2 diabetes, stage PSA, Gleason score, primary treatment 1. Risk analysis: (A) Current use was associated with a lower risk of lethality regardless of duration. Compared with never use, past regular aspirin use among men initially free of diagnosed cancer was associated with a lower risk of lethal PC regardless of time since quitting. (B) Associations between aspirin and reduced lethal PCa did not hold among cases diagnosed in the PSA era. 2. Survival analysis: (A) Compared with never users, current postdiagnostic use among men diagnosed with nonlethal PC was associated with a lower risk of lethality (HR 0.68, 95% CI 0.52-0.90) regardless of duration. Past postdiagnostic use was associated with a higher risk of lethality (HR 1.50, 95% CI 1.10-2.05). (B) Associations between current postdiagnostic aspirin and improved survival did not hold for cases diagnosed in the PSA era. 6537 PCa cases from both study arms 5-ARI/alpha-blockers use PCa-specific mortality a AC: medication use, Gleason score, clinical tumor stage, PSA level at diagnosis, use of other drug groups, simultaneous usage of alpha-blockers or 5-ARIs No formal adjustment for primary treatment 1. Prediagnostic 5-ARI use (vs nonuse) was not associated with the risk of PCa death. Stratification by amount, duration, or intensity of 5-ARI use showed no survival trends. Postdiagnostic 5-ARI usage was not significantly associated with PCa survival. No risk associations by amount, duration, or intensity of use were observed. In cases with >10 yr of follow-up, no association was observed between pre/postdiagnostic use and PCa-specific survival. 2. In prediagnostic alpha-blocker users, PCa-specific survival was worse (HR 1.29; 95% CI 1.08-1.54), with no difference in overall survival. Postdiagnostic alpha-blocker usage was associated with increased risk of PCa death (HR 1.56, 95% CI 1.30-1.86; ongoing use: HR 1.46, 95% CI 1.15-1.84; discontinued use: HR 1.67, 95% CI 1.32-2.11). Worse PCa-specific survival was observed only during the first 5 yr of usage, with the risk difference disappearing in longer use. The increased risk of PCa death was especially high in cases diagnosed in the screening arm and in those using antidiabetic drugs also. When the analysis was limited to include only cases with >10 yr of follow-up after diagnosis, both pre-and postdiagnostic alpha-blocker usage were not significantly associated with increased mortality. Oral anticoagulants use Incidence of total, lowgrade, high-grade (GS !7) PCa AC: education, diabetes, BMI, statin use1. Ever use of oral anticoagulants was not significantly associated with the risk of PCa (a weak, inverse, non-statistically significant association was found). The association did not vary substantially according to time since first use, duration of use, current use, age at first use, or indication. 2. Similar results were observed among patients screened within the last 2 yr and with regard to cancer aggressiveness. 3. There was no evidence that the inverse association was greater with increasing length of time since diabetes diagnosis. 4. Among controls, men with diabetes had marginally lower PSA levels than those without diabetes (geometric means: 0.915 vs 1.03 ng/ml; p = 0.15). In a sensitivity analysis investigating whether the reduced odds of PCa resulted from undetected PCa, the association was not significant (OR "adjusted" for possible differential misclassification 0.82 [0.65-1.03], p = 0.09). Hypercholesterolemia 3. There were no associations between total n-3 or n-6 polyunsaturated fatty acids and risk of overall or any subset of PCa, nor was there any association with the ratio of n-6/n-3 fatty acids. 4. There were no associations between any of these of individual fatty acids and nonadvanced PCa. 5. ALA intake was related to increased risk of advanced PCa (HR 1.17; 95% CI 1.04-1.31). 6. There were no significant interactions between PSA screening and the results for saturated fat, ALA or EPA. Isoflavones In these analyses, calcium intake, dietary calcium, and calcium from supplementary sources were each independently associated with an elevated risk of advanced disease. When total calcium intake and total dairy products were modeled simultaneously, a positive trend remained for calcium, but not for dairy products. A similar result was obtained when calcium intake was modeled simultaneously with lactose intake. 3. In this study, analyses were not formally adjusted for PSA screening, and therefore less frequent PCa screening could have led to a more advanced stage of diagnosis. However, men with higher calcium intake had actually had PSA tests slightly more frequently than those with lower intakes. 1. No significant association was found between the intakes of fruits and total vegetables, and risk of total PCa after adjustment for all potential confounding factors, including history of screening examinations. 2. No specific vegetable group was significantly associated with the risk of total PCa. 3. Neither fruit nor total vegetable intake showed a significant inverse association with localized or advanced PCa. No specific vegetable group showed a significant association with either localized or advanced PCa. 4. To weaken the influence of cancer detected by PSA screening, analyses were performed to test the association between fruit and vegetable intake, and total PCa after excluding screening-detected tumors. Fruit consumption was not associated with total PCa, as well as total vegetable consumption. 5. In stratified analyses by cohort, age, smoking status, and BMI, and in the analysis that excluded vitamin supplement users, no significant inverse association was observed between the consumption of fruits and total vegetables or subtypes, and risk of total PCa. 1. There was no evidence of an association of processed red meat, unprocessed red meat, or fish with PCa progression.
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Fruits and vegetables
2. An increased risk of PCa progression was associated with higher poultry intake, which was not statistically significant 3. A significant two-fold increased risk of PCa progression was seen among men in the highest quartile of egg intake compared with men in the lowest quartile (HR 2.02; 95% CI 1.10, 3.72), which appeared to be limited to the highest level of intake. In secondary analyses excluding patients with lack of data on biological evidence of recurrence, the results for egg consumption remained positive but became nonsignificant. 4. There was an interaction between prognostic risk, total poultry, and risk of PCa progression. Greater poultry intake was associated with an increased risk of progression among men with high prognostic risk, but there was no association among men with low/ intermediate prognostic risk (p for interaction 0.003). Tomaszewski 1153 PCa patients treated for T1-T2c PCa AC: total energy intake, months between diagnosis and questionnaire, BMI, total caloric intake, methionine, and vitamin B2, B6, and B12 intake 1. Total or dietary folate intake was not associated with PCa recurrence. 2. On secondary analysis stratified by treatment, patients in the lowest decile of dietary folate intake (range 123-252 mg) were at a 2.6-fold increase risk of progression after RP (HR 2.56, 95% CI 1.23-5.29, p = 0.01), although total folate was not associated with risk. In patients treated with EBRT and BT, we observed no evidence of an association between PCa progression and increased intake of total or dietary folate. related diseases or arthritis, despite a lack of significant interaction.
Finally, in a PBCC study [28] , ever use of aspirin (odds ratio [OR] 0.82 [95% CI 0.68-0.99]), daily use (OR 0.78 [95% CI 0.64-0.95]), and daily low-dose use (OR 0.71 [95% CI 0.56-0.90]) were associated with a reduced risk of overall PCa. Daily low-dose use of aspirin was associated with a decreased risk of both less and more aggressive PCa. Current and long-term users had a decreased risk of PCa compared with nonusers, while former users did not.
3.1.1.4. Nonaspirin nonsteroidal anti-inflammatory drugs. In the PLCO cohort [27] , there was no evidence of an association between ibuprofen use and PCa risk. Nonetheless, this was in part likely attributed to the low prevalence of ibuprofen use among participants.
In the FinRSP study cohort [29] , current use of nonsteroidal anti-inflammatory drug (NSAID) prescription (compared with nonuse), but not previous or over-the-counter use, was associated with an increased risk of PCa (HR 1.45, 95% CI 1.33-1.59, and HR 1.32, 95% CI 1.10-1.59 in the screening and control arms, respectively). A similar risk association was also observed for the use of acetaminophen and coxib, but not for aspirin. The increased PCa risk was not modified by tumor grade. Current (but not previous) use of NSAIDs, coxibs, and acetaminophen was also associated with an increased risk of metastatic PCa in both trial arms. The authors concluded that, taken together, these findings do not seem to support causal associations but rather protopathic bias (due to treatment of symptoms of undiagnosed PCa, presumably pain due to metastases), given that risk elevation was observed only for ongoing use, was strongest for metastatic disease, did not differ by amount or duration of use, and was noted for NSAIDs and acetaminophen (that has a different mechanism of action), but not for aspirin (which is mainly used for prevention of cardiovascular and cerebrovascular disorders and less often as analgesic). The modest risk elevation for localized and lowgrade PCa, evident in both study arms (thus not likely explained by more active screening), was not dose dependent, suggesting that the indications for NSAID usage were likely behind this association.
A PCS from the Cancer Prevention Study (CPS)-II nutrition cohort [30] showed that, while current regular acetaminophen use (regardless of duration) was not associated with PCa risk, long-term regular use (!5 yr) was associated with lower risks of both total (HR 0.62, 95% CI 0.44-0.87) and aggressive (risk ratio [RR] 0.49, 95% CI 0.27-0.88) PCa.
Finally, in a PBCC study [28] , there were no associations between the use of nonaspirin NSAIDs, including ibuprofen and acetaminophen, and PCa risk.
3.1.1.5. 5-Alpha reductase inhibitors. In a study from the HPFS cohort with 14 yr of follow-up [17] , ever (vs never) use of 5alpha reductase inhibitors (5-ARIs) was associated with a 23% lower risk of overall PCa (HR 0.77,; 95% CI 0.65-0.91) and a decreased risk of intermediate-(Gleason score [GS] 7; HR 0.67, 95% CI 0.49-0.91) and low-grade (GS 2-6; HR 0.74, 95% CI 0.57-0.95) PCa, but not with high-grade (even including GS 4 + 3 = 7) or lethal PCa. However, the number of patients with high-grade or lethal PCa was limited. Analyses among men who underwent PSA testing in 1996 showed very similar results to the primary analyses.
3.1.1.6. Oral anticoagulants. In a PBCC study [21] , ever use of oral anticoagulants was not associated with the risk of PCa. The association did not vary according to the duration of use, age at first use, or indication. Similar results were observed with regard to cancer aggressiveness. In one PCS from the HPFS cohort [31] , no significant association with lethal PCa (defined as M+ or PCa-specific death) was reported for both postdiagnostic current statin use and duration of use (!6 yr vs none). There was evidence of effect modification by disease stage: among men diagnosed with T2+ PCa, current use of statins was associated with a reduced risk of lethal PCa (HR 0.65, 95% CI 0.43-0.97), whereas there was no association among those diagnosed with T1 disease.
In the study from the FinRSP cohort [32] , postdiagnostic active statin use was associated with a decreased risk of PCa death (adjusted HR [aHR] 0.80, 95% CI 0.65-0.98), while prediagnostic statin use was not. The risk decreased in an inverse association with the intensity of statin use. The risk decrease was significant among men with low/medium-risk cancer (according to EAU guidelines) at baseline. Of note, survival was significantly improved only in men with androgen deprivation therapy (ADT) as the primary treatment and among men who were not using antihypertensive drugs. No risk reduction was observed for users of nonstatin cholesterol-lowering drugs. In this study, the associations were not likely explained by more active screening participation among statin users; moreover, risk of healthy-user bias appeared to be low, as statin users were not healthier but instead had a higher prevalence of medication use for comorbid conditions compared with the nonusers. In addition, a decreased risk among postdiagnostic statin users persisted when deaths due to cardiovascular causes were analyzed as competing causes of death (HR 0.39, 95% CI 0.32-0.49; Table 1 ).
3.1.2.2. Aspirin. In one PCS from the Physicians' Health Study cohort [33] , current postdiagnostic regular aspirin use (>3 tablets/wk for at least 1 yr) was associated with lower risk of lethality (M+ or PCa-specific death; HR 0.68, 95% CI 0.52-0.89), regardless of duration. Accordingly, current postdiagnostic use (vs never use) among men diagnosed with nonlethal PCa was associated with lower risk of lethality (HR 0.68, 95% CI 0.52-0.90), regardless of duration. However, both associations did not hold among cases diagnosed in the PSA era.
3.1.2.3. 5-ARIs and alpha-blockers. In one PCS from the FinRSP cohort [34] , prediagnostic 5-ARI use (vs nonuse) was not associated with the risk of PCa death. As such, previously reported increased proportion of high-grade cases does not seem to affect PCa-specific survival, at least in the short term, and at the same time, previously reported decrease in overall PCa risk does not seem to translate into improved survival. Taken together, these findings may suggest that 5-ARIs impact predominantly the occurrence of low-risk disease unlikely to progress into fatal stage, rather than development of aggressive disease. Postdiagnostic 5-ARI use was not significantly associated with PCa survival.
Both pre-and postdiagnostic alpha-blocker use was associated with worse PCa-specific survival (HR 1.29, 95% CI 1.08-1.54, and HR 1.56, 95% CI 1.30-1.86, respectively). However, worse survival was observed only during the first 5 yr of usage. When the analysis was limited to cases with >10 yr of follow-up after diagnosis, associations were no longer significant. Taken together, these associations are likely noncausal and caused by the underlying indications for drug usage rather than by the drug itself. For postdiagnostic use, this suggests that lower urinary tract symptoms after PCa diagnosis might be indicative of PCa progression.
3.1.2.4. Antiarrhythmic drugs. In one PCS from the FinRSP cohort [35] , prediagnostic digoxin use was not significantly associated with the risk of PCa death and postdiagnostic use was not significantly associated with PCa survival, with no consistent differences by cumulative amount and duration of use. These findings suggest that the potentially lower risk of Gleason 7-10 PCa in men under systematic PCa screening [36] does not translate into improved disease-specific survival. A significant risk decrease was observed only among men not receiving ADT and using digoxin before diagnosis (HR 0.20, 95% CI 0.048-0.86). Neither pre-nor postdiagnostic sotalol use was associated with a risk of PCa death.
Metabolic diseases and PCa
Overall, 11 reports from seven studies were included, with 10 on PCa incidence and one on PCa survival ( [19, 37] , one nested case-control (NCC) study [38] , and one PBCC study [22] .
In the study from the HPFS cohort [37] , a higher BMI at age 21 was associated with a significantly lower risk of lethal, advanced, and Gleason 7 PCa (adjusted RRs in the range of 0.69-0.77 comparing BMI 26 with BMI 20-22), although a significant trend was seen only for advanced and Gleason 7 PCa. There was a weak inverse association with total, nonadvanced, and low-grade PCa. However, for this association, detection bias (reduced PCa detection in obese men as a consequence of PSA hemodilution and/or reduced diagnostic performance due to larger prostate volumes) cannot be ruled out entirely. Associations of BMI at age 21 and adult BMI and PCa were attenuated when additionally adjusting for childhood body shape, or for mutual adjustment for BMI in early or late adulthood, respectively; this may suggest that body size in early adulthood might be more strongly related to PCa development than body size later in life.
In the study from the PLCO cohort [19] , BMI >30 (compared with BMI 18.5-25) at age 20 and 50, and at baseline was associated with a decreased risk of total PCa (HR [95% CI] 0.82 [0.68-0.99], 0.87 [0.81-0.94], and 0.93 [0.87-1.00], respectively). BMI (at any age, mean, maximum) was not associated with PCa aggressiveness. Risk of detection bias could not be ruled out.
In the NCC study from the ProtecT study cohort [38] , there was no evidence of any important relationship between BMI and PSA-detected total PCa. However, a weak association between BMI and low-grade PCa (p trend 0.045; BMI !30 vs <25: OR 0.76, 95% CI 0.59, 0.97) was reported. In this study, the risk of detection bias appeared to be low.
Finally, in a PBCC [22] [22, 23, 37, 38] .
In a PBCC study [22] , increased WC (>102 cm), after adjustment for BMI, was associated with an increased risk of overall (OR 1.23 [95% CI 1.05-1.46]) and high-grade (OR 1.47 [95% CI 1.22-1.78]) PCa.
In the HPFS cohort [37] , higher WC was associated with a lower risk of nonadvanced (aRR for top vs bottom quintile: 0.93, 95% CI 0.82-1.04, p trend 0.03), Gleason 7 (aRR 0.84, 95% CI 0.70-1.00, p trend 0.02), and low-grade PCa (aRR 0.88, 95% CI 0.75-1.02, p trend 0.01), but not with the risk of total PCa. However, the observed associations were weakened when adjusting for either childhood body shape or adult BMI. Moreover, these findings might have potentially been influenced by the detection bias.
In the NCC study from the ProtecT study cohort [38] , there was no evidence of any important relationship between WC and PSA-detected total or stage-/grade-specific PCa. Similarly, in a PCS from the CPS-II nutrition cohort [23] , there was no significant association between WC and PCa risk after adjustment for BMI.
3.2.1.2.3. Waist-to-hip ratio. In a PBCC [22] , a weak association was found between waist-to-hip ratio (WHR) and highgrade PCa (OR 1.20 [95% CI 1.01-1.43]) in analyses adjusted for BMI; however, in subgroup analyses according to BMI categories, no significant associations were observed.
In the NCC study from the ProtecT study cohort [38] , there was no evidence of any important relationship between WHR and PSA-detected PCa. Associations for nonadvanced PCa were similar in the pre-PSA and PSA eras. However, in the pre-PSA era, total PCa risk appeared to be lower and the decreased risk associated with DM seemed to be stronger for high-grade (vs lowgrade) disease. There was a significant trend of a decreased risk of total PCa with increasing time since DM diagnosis.
In a PCS involving 1 million men in Israel [40] , men with incident DM were at a higher risk of total PCa during the 1 st year following diabetes diagnosis, while the risk decreased by the 3rd and subsequent years (HR [95% CI] 0.89 [0.84, 0.95]), as it was for the prevalent diabetes group (0.80 [0.76, 0.85]). This was observed for low-medium-grade (0.83 [0.77, 0.89]) but not for high-grade (GS 7-10) PCa. Of note, mean PSA values were significantly lower for men with diabetes. As such, the reduced risk of low-moderate-grade but not of high-grade PCa among men with DM may suggest a potential detection bias.
In the NCC study from the ProtecT study cohort [41] , presence of DM was associated with a reduced risk of total (OR 0.78 [95% CI 0.61-0.99]), localized (T1-T2; 0.76 [0.59-0.98]), and well-differentiated (ie, low-grade; GS 6; OR 0.69 [0.52-0.93]) PCa. There was no evidence that the inverse association was greater with increasing length of time since diabetes diagnosis. In additional analyses excluding PCa cases diagnosed in the 1st year after DM diagnosis, or in patients with data on BMI, the association was no longer significant. Of note, among controls, men with DM had marginally lower PSA levels; in a sensitivity analysis, the OR "adjusted" for possible differential misclassification was 0.82 (95% CI 0.65-1.03; p = 0.09). In this study, both selection bias and surveillance bias were unlikely. 3 [39] , longterm weight gain was not associated with an increased risk of lethal PCa in overall population. However, risk was increased in selected subgroups (never smokers, men with BMI !25 at age 21, and men surviving !4 yr after diagnosis, especially if never smokers). Short-term weight gain (over 4 or 8 yr before diagnosis) was not associated with the risk of lethal PCa in the overall study population, but the risk was increased in men with a BMI of !25 at age 21 and in men who gained >5 pounds in the 8 yr prior to diagnosis. BMI at age 21 and BMI at diagnosis were not significantly associated with the risk of lethal PCa. Finally, weight change and obesity (BMI) were not associated with an increased risk of biochemical recurrence. The authors concluded that, according to these findings, weight gain might have an early influence on prostatic carcinogenesis and might play a role in the development of tumors more likely to progress. However, the risk of detection bias cannot be entirely ruled out, and it may be difficult to disentangle the reciprocal influence of obesity and weight gain.
Dietary factors and PCa
Overall, 12 reports from seven studies were included, of which eight were on PCa incidence and three on PCa recurrence, progression, or survival ( [44] , intakes of total fat, polyunsaturated fat, total trans-fatty acids, total n-3 or n-6 polyunsaturated fatty acids, and n-6/n-3 fatty acid ratio were not associated with PCa risk. On the contrary, intake of saturated fat and ALA was associated with an increased risk of advanced PCa (HR 1.21, 95% CI 1.00-1.46, and HR 1.17, 95%CI 1.04-1.31, respectively).
Isoflavone and phytoestrogen intakes.
In a PCS from the PLCO cohort [45] , no statistically significant association was observed between intake of total isoflavones and risk of total or nonadvanced PCa. On the contrary, dietary intake of total isoflavones was associated with an increased risk of advanced PCa (HR [95% CI] 1.91 [1.25-2.92]; p trend 0.007).
3.3.1.3. Meat intake. In a PCS from the PLCO cohort [46] , there was no association of red or white meat consumption, processed meat consumption, and meat-cooking method with the risk of total or advanced PCa. However, in another analysis, consumption of >10 g/d of very well-done meat was associated with an increased risk for total (RR 1.42, 95% CI 1.05-1.92; p trend = 0.02) and incident (RR 1.69, 95% CI 1.19-2.40; p trend = 0.003), but not advanced, PCa. While 2amino-1-methyl-6-phenylimidazo [4,5-b] pyridine intake was associated with an increased risk for overall and incident (but not advanced) PCa, intakes of 2-amino-3,4,8trimethylimidazo[4,5-f]quinoxaline, heterocyclic amines 2-amino-3,8-dimethylimidazo [4,5-b] quinoxaline and benzo(a)pyrene, as well as overall mutagenic activity from meat were not associated with PCa risk.
In a PCS from the NIH-AARP Diet and Health Study cohort [47] , red meat intake was associated with an increased risk of all PCa, the associations being stronger for advanced disease. Grilled/barbecued meat was associated with the risk of both total and advanced PCa. Processed meat intake was also associated with an increased risk of advanced PCa. Moreover, there was an increased risk of 10% per 10-g increase in red processed meat intake (95% CI 1.03, 1.17; p trend 0.003).
3.3.1.4. Fish intake. In a PCS from the Physician's Health Study cohort with 19 yr of follow-up [48] , total fish intake was unrelated to PCa risk, even in stratified analyses according to PCa stage, grade, lethality, and date of diagnosis.
3.3.1.5. Calcium intake. In a PCS from the HPFS cohort [49] , no significant trend was noted for calcium intake and risk of total PCa, although a statistically significant higher risk was observed for high (>2 g/d) vs low (0.5-0.75 g/d) intake for overall, high-grade (GS >7), and advanced PCa. The association with high-grade PCa remained significant after adjustment for phosphorus intake. Of note, in this study, analyses were not adjusted for PSA testing, and therefore less frequent PSA testing could have led to a more advanced PCa stage at diagnosis. However, men with higher calcium intake actually had PSA tests slightly more frequently than those with lower intake.
3.3.1.6. Fruit and vegetable intakes. In the Japan Public Health Center-Based Prospective Study [50] , no significant association was found between fruit and total (or specific group) vegetable intakes and the risk of total or stage-specific PCa. These findings were confirmed by the Japan Collaborative Cohort Study for Evaluation of Cancer Risks [51] , where vegetable intake, as well as beta-carotene intake, was not associated with PCa risk. In this study, there was also no significant trend of increased risk of PCa with increasing intake of alpha-carotene.
Dietary factors and PCa recurrence, progression, and survival
In a PCS from the Diet and Lifestyle substudy cohort of Cancer of the Prostate Strategic Urologic Research Endeavor [52] , there was no evidence of an association between intake of red meat or fish and PCa progression. No significant association was found for higher poultry intake, as well as for egg intake (after excluding patients with lack of biological evidence of recurrence). However, greater poultry intake was associated with an increased risk of progression among men with high (but not low-intermediate) prognostic risk PCa (p for interaction = 0.003).
In another study from the same cohort in men with M0 disease at presentation [53] , total folate and dietary folate intake was not associated with PCa recurrence. However, patients with severely deficient dietary folate intake (lowest decile, range 123-252 mg) were at a 2.6-fold increase risk of PCa progression after radical prostatectomy (HR 2.56, 95% CI 1.23-5.29, p = 0.01).
Finally, in a PCS from the Physicians' Health Study cohort [54] , there was an increased risk of PCa death among men who consumed greater amounts of saturated fat after diagnosis. However, PCa death was a secondary outcome in this study due to the small number of events.
Limitations at study and review levels
The evidence provided in our review must be critically interpreted considering the potential limitations at both review and study levels (described in detail in the Supplementary material). In brief, the review strategy might not have been able to identify all relevant studies on the topics of interest. Moreover, our review included only the latest evidence available and only studies focusing on PSA-screened populations.
Definitions of exposure to the specific risk factors considered in this review were variable across the studies. In particular, among studies evaluating the potential impact of drugs on PCa risk, information on exact dose, frequency, and length of treatment was rarely reported (Table 1 and Supplementary Table 3 ).
Selection of studies was driven by a specific PICOS framework, leading to potential exclusion of relevant studies due to insufficient reporting of the information required for assessing study eligibility. In addition, our PICOS framework might have led to exclusion of studies evaluating specific risk factors considered in the review plan (ie, antihypertensive drugs or testosterone replacement therapy; Supplementary material).
This systematic review was not designed to evaluate associations between drugs, metabolic diseases, and dietary factors in men undergoing regular screening for PCa, but rather in men exposed to PSA testing.
Although all studies included in the review adjusted statistical analyses for the rate of PSA testing, the heterogeneous definitions and measurements of this covariate across studies, as well as the variable rates of PSA testing among populations ( Supplementary Table 3 ), might have led to heterogeneous extent of "adjustment," increasing the RoB. Moreover, specific information on indications, methods, and frequency of diagnostic ascertainment of PCa was rarely reported in most reports included in the review, increasing the risk of detection bias. As such, we could not evaluate the extent to which the patient's comorbidity burden or life expectancy might have influenced decision to perform PSA testing and/or undergo further diagnostic evaluation.
However, these limitations at a study level are grounded in the highly heterogeneous prevalence of PSA testing among different populations [4, 5] , the diversity in recommendations on the use of PSA testing and type of diagnostic ascertainment provided over time by different organizations worldwide [5, 9] , and the lack of information on the purpose of PSA testing in most studies on PCa risk factors.
For these reasons, it is not possible to make inferences on the impact of the risk factors evaluated in our review on PCa risk in the context of standardized screening protocols.
It is important to note that competing risks of mortality may have resulted in reduced PCa detection (and thus PCa risk) in observational studies focused on associations between risk factors and PCa incidence. As not all studies included in our review performed formal competing-risk regression analyses (Tables 1-3) , the possibility of a detection bias cannot be entirely ruled out.
Although we included only studies with extensive follow-up, it might have still been limited to evaluate some PCa outcomes, considering its long natural history.
The findings of this review may not be generalizable to all men exposed to PSA testing, as results of several studies were themselves of limited generalizability (Supplementary Table 4 ).
Finally, due to the overall low quality of evidence and the several limitations of included studies (Supplementary material), causality of associations between risk factors and PCa risk is uncertain; as such, the evidence provided cannot be directly translated in a public health perspective.
Conclusions
Elucidation of potentially modifiable risk factors for PCa has been hindered by differences in PSA testing among populations worldwide. Our systematic review provided a detailed overview of the latest evidence from long-term observational studies on Table 4 -Overview of collective evidence from our systematic review on the effect on PCa risk of those factors for which evidence was available.
Topic (outcome)
Summary of findings the role of selected, partially modifiable risk factors for PCa considering the impact of PSA testing on PCa diagnosis. For some risk factors, evidence was insufficient to assess potential effects, while for others there was no evidence of an effect. For selected risk factors, there was low-quality evidence of modest effects on PCa risk (Table 4) .
Given the burden of PCa and the increasing prevalence of many of the risk factors evaluated in our review among populations worldwide, even modest effects of such factors on PCa risk might theoretically represent key drivers for public health interventions. However, judgments on potential implications of our collective findings are beyond the scope of this review.
Our review distinctly highlights the need for further high-quality research in this field. Future studies are needed to confirm the associations suggested by our review, taking into account the multifactorial etiological background of PCa, exploring their potential biological explanations and selecting those risk factors most likely to trigger effective public health interventions.
